Real-World Experience of Using Next-Generation-Sequencing in Multiple Myeloma Diagnostics in the UK National Health Service
Clinical Lymphoma Myeloma and Leukemia · 2026-10
DOI: 10.1016/j.clml.2026.10.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Sina A Beer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; Department of Haematology, Royal Marsden Hospital, London, UK. Die Arbeit nennt 16 Literaturangaben. Gefördert von: The National Institute for Health Research Biomedical Research Centre for cancer, Myeloma UK, The Royal Marsden Cancer Charity.
Abstract (Originalsprache)
The IMS-IMWG 2025 updated definition of high-risk multiple myeloma (HRMM) introduced next-generation sequencing (NGS) based detection of TP53 single-nucleotide variants (SNV) as an independent high-risk factor. However, most published data on TP53 SNVs in MM derive from exploratory research studies using NGS interpretation pipelines outside of quality-controlled, clinically accredited laboratories, with limited information on co-occurring high-risk cytogenetic abnormalities (HRCA). To address this, we retrospectively reviewed all transplant-eligible newly diagnosed MM (NDMM) patients treated at the Royal Marsden Hospital in the UK between February 2021 and April 2026 who underwent standard-of-care parallel fluorescence in situ hybridization (FISH) testing for all IMS-IMWG consensus genomic staging (CGS) criteria and NGS-based TP53 SNV calling in the National Health Service diagnostically accredited Genomic Laboratory Hub (GLH). A total of 102 patients were included. Based on FISH, 24 patients (23.5%) fulfilled IMS-IMWG CGS criteria for HRMM, including 8 (7.8%) with del(17p) and 5 (4.9%) with biallelic del(1p32). All 24 patients had co-occurrence of 2+ HRCA, including all 5 patients with biallelic del(1p32). NGS identified 4 cases (3.9%) with TP53 mutations, of which 2 harbored del(17p), while 2 were classified as HRMM solely based on NGS results. However, both isolated TP53mut also carried additional HRCA. Thus, in this standard-of-care diagnostic setting, only 2% of NDMM were re-classified based on NGS findings and, notably, all 26 HRMM had 2+ high-risk lesions. Although limited by cohort size and lack of survival outcomes, these descriptive data demonstrate genomic co-occurrence rather than independent prognostic value and support a continued focus on reliable, quality-controlled detection of structural variants alongside NGS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; Department of Haematology, Royal Marsden Hospital, London, UK.
- Department of Haematology, Royal Marsden Hospital, London, UK.
- University Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino,…
- Clinical Genomics, Centre for Molecular Pathology, Royal Marsden Hospital NHS Trust, London, UK.
- Department of Haematology, Royal Marsden Hospital, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; Department of Haematology, Royal Marsden Hospital, London, UK. Electronic address: martin.kaiser@icr.ac.uk.
Förderung
- The National Institute for Health Research Biomedical Research Centre for cancer
- Myeloma UK
- The Royal Marsden Cancer Charity
Zitieren
APA
Beer, S. A., Seneca, E., Bertuglia, G., Proszek, P., Thornton, T., Hubank, M., Patrizan, M. V., El-Sharkawi, D., Smith, K., Pawlyn, C., Boyd, K., & Kaiser, M. F. (2026). Real-World Experience of Using Next-Generation-Sequencing in Multiple Myeloma Diagnostics in the UK National Health Service. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.10.006
Vancouver
Beer SA, Seneca E, Bertuglia G, Proszek P, Thornton T, Hubank M, et al. Real-World Experience of Using Next-Generation-Sequencing in Multiple Myeloma Diagnostics in the UK National Health Service. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.10.006
BibTeX
@article{Beer2026,
author = {Beer, Sina A and Seneca, Elisa and Bertuglia, Giuseppe and Proszek, Paula and Thornton, Tracey and Hubank, Michael and Patrizan, Mikel Valganon and El-Sharkawi, Dima and Smith, Katy and Pawlyn, Charlotte and Boyd, Kevin and Kaiser, Martin F},
title = {Real-World Experience of Using Next-Generation-Sequencing in Multiple Myeloma Diagnostics in the UK National Health Service},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2026.10.006}
}
EUVIMED